Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease.

Autoimmune hypoglycemia belongs to the clinical spectrum of HHV8+ MCD and rituximab is an effective treatment of this condition. This rare complication is related to autoantibodies directed toward the insulin receptor and activating the insulin signaling pathway.